Jennifer Gray Tomilov, PhD | Authors


For Advanced Heme Malignancies, CAR T Cells Overcome Exhaustion, Tumor Escape

December 28, 2019

Progress in the development of chimeric antigen receptor T-cell therapy and other cell-based therapies has led to new therapeutic options for advanced malignancies. CAR T-cell agents approved by the FDA in recent years include axicabtagene ciloleucel for diffuse large B-cell lymphoma and tisagenlecleucel for both DLBCL and acute lymphoblastic leukemia.